NewsOK Local Stocks
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Incyte Corp (NQ: INCY)
78.51 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 5:50 PM EDT, Oct 22, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 78.51
Bid (Size) 77.20 (1)
Ask (Size) 79.55 (1)
Prev. Close 78.51
Today's Range 78.51 - 78.51
52wk Range 57.00 - 89.30
Shares Outstanding 211,969,163
Dividend Yield N/A
Performance
YTD
+23.52%
+23.52%
1 Month
+1.12%
+1.12%
3 Month
N/A
N/A
6 Month
+4.11%
+4.11%
1 Year
+20.45%
+20.45%
Top News
More News
Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
Research from Taltz®, Olumiant® and mirikizumab highlight the impact Lilly's medicines may have for patients around the world Read More
from PR Newswire
Incyte to Present at Upcoming Investor Conference
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 8:35 am (MST) / 10:35 am (EST) in... Read More
from Business Wire News Releases
More News
Read More
Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
from Business Wire News Releases
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
from Business Wire News Releases
Incyte to Report Third Quarter Financial Results
from Business Wire News Releases
BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals
from GlobeNewswire News Releases
Interesting INCY Put And Call Options For June 2020
category Stocks
from Market News Video
CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
from Business Wire News Releases
Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
from Business Wire News Releases
Incyte Takes Over #309 Spot From Mettler-Toledo International
category Stocks
from Market News Video
Incyte to Host Investor Conference Call from ESMO 2019
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.